Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein
Open Access
- 1 January 2019
- journal article
- research article
- Published by Taylor & Francis Ltd in Emerging Microbes & Infections
- Vol. 8 (1), 516-530
- https://doi.org/10.1080/22221751.2019.1597644
Abstract
The Middle-East respiratory syndrome coronavirus (MERS-CoV) is a zoonotic virus that causes severe and often fatal respiratory disease in humans. Efforts to develop antibody-based therapies have focused on neutralizing antibodies that target the receptor binding domain of the viral spike protein thereby blocking receptor binding. Here, we developed a set of human monoclonal antibodies that target functionally distinct domains of the MERS-CoV spike protein. These antibodies belong to six distinct epitope groups and interfere with the three critical entry functions of the MERS-CoV spike protein: sialic acid binding, receptor binding and membrane fusion. Passive immunization with potently as well as with poorly neutralizing antibodies protected mice from lethal MERS-CoV challenge. Collectively, these antibodies offer new ways to gain humoral protection in humans against the emerging MERS-CoV by targeting different spike protein epitopes and functions.Funding Information
- European Federation of Pharmaceutical Industries and Associations
- NIH (2PO1AIO6O699)
- Center for Scientific Review
- China Scholarship Council
This publication has 48 references indexed in Scilit:
- Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigationThe Lancet Infectious Diseases, 2013
- The Receptor Binding Domain of the New Middle East Respiratory Syndrome Coronavirus Maps to a 231-Residue Region in the Spike Protein That Efficiently Elicits Neutralizing AntibodiesJournal of Virology, 2013
- Development of a Highly Protective Combination Monoclonal Antibody Therapy against Chikungunya VirusPLoS Pathogens, 2013
- Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMCNature, 2013
- Crosstalk between Human IgG Isotypes and Murine Effector CellsThe Journal of Immunology, 2012
- Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal AntibodiesScience Translational Medicine, 2012
- A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A HemagglutininsScience, 2011
- Acquisition of Complement Resistance through Incorporation of CD55/Decay-Accelerating Factor into Viral Particles Bearing Baculovirus GP64Journal of Virology, 2010
- Developments towards effective treatments for Nipah and Hendra virus infectionExpert Review of Anti-infective Therapy, 2006
- Novel Human Monoclonal Antibody Combination Effectively Neutralizing Natural Rabies Virus Variants and Individual In Vitro Escape MutantsJournal of Virology, 2005